: Pharmacological therapy is the cornerstone of chronic heart failure treatment. However, an increasing number of devices for monitoring and treatment of patients with heart failure are being used and developed to complement existing therapies. Pulmonary and systemic congestion, left ventricular remodeling, neurohormonal activation, low cardiac contractility and impaired cardiac output are the main pathophysiological targets of these devices. The aim of this review is to summarize rationale, functioning, evidence and current indications regarding new devices for the management of patients with chronic heart failure.
[Transcatheter devices for chronic heart failure: state of the art]
Emdin, Michele;Porto, Italo;Sinagra, Gianfranco;
2022-01-01
Abstract
: Pharmacological therapy is the cornerstone of chronic heart failure treatment. However, an increasing number of devices for monitoring and treatment of patients with heart failure are being used and developed to complement existing therapies. Pulmonary and systemic congestion, left ventricular remodeling, neurohormonal activation, low cardiac contractility and impaired cardiac output are the main pathophysiological targets of these devices. The aim of this review is to summarize rationale, functioning, evidence and current indications regarding new devices for the management of patients with chronic heart failure.| File | Dimensione | Formato | |
|---|---|---|---|
|
02 Pancaldi (5-18).pdf
embargo fino al 18/07/2024
Tipologia:
Documento in Pre-print/Submitted manuscript
Licenza:
Dominio pubblico
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
